Sustained Partial Response to Afatinib in a Patient With Lung Adenocarcinoma Harboring HER2^V659E Mutation

Abstract

our knowledge, this is the third reported case and the longest PR case reported, as indicated by a literature search using PubMed and Web of Science for HER2 V659E TMD mutation in lung adenocarcinoma that responded well to afatinib treatment.In conclusion, afatinib is effective for lung adenocarcinoma with HER2 V659E TMD mutation. Establishing a database of clinical genomic and therapeutic outcomes of patients with less common mutations may be essential for precision oncology treatment.